Firstime Venture Capital

Firstime Venture Capital, based in Tel Aviv, is an Israeli venture firm with a thesis spanning sustainability, climate, and adjacent areas including digital wellness and digital health. The fund’s healthcare investments tend to sit at the intersection of modern lifestyle, accessibility, and care delivery, with a working assumption that consumer-driven wellness and clinically credible health products are converging into a single category that demands both technological seriousness and commercial reach.

For AI healthcare founders, the relevant thesis covers consumer wellness platforms with serious data backbones, digital health products that improve accessibility of care, behavioral health and lifestyle medicine tools, and software that addresses environmental and lifestyle drivers of health. Pure clinical workflow software, devices, and biotech are not central. Companies whose AI is decorative rather than substantive, or whose only differentiation is brand and marketing, will not fit the thesis.

Check sizes range from $1M to $5M at entry, deployed at seed, Series A, and Series B. Firstime participates as a lead or co-lead in priced rounds and reserves capital for follow-on. Geography is principally Israel, with portfolio companies typically operating globally and pursuing the US and Europe as primary commercial markets. Syndicate partners include Israeli early-stage specialists and US consumer and health-focused investors. Reserve strategy is meaningful, and follow-on participation is expected as companies progress.

The team includes investment partners with backgrounds in venture, consumer technology, and operations across adjacent industries. Board engagement at seed and Series A tends to be hands-on, with help focused on commercial strategy, brand and product positioning, and downstream financing. The fund operates with enough operational depth to be useful to consumer-facing companies, which often need different support than pure enterprise plays.

Founders should approach Firstime with a coherent story about how the product sits at the intersection of wellness, accessibility, and credible health outcomes, and how AI is the substantive engine for differentiation rather than a marketing label. Introductions through Israeli early-stage VCs, US consumer health investors, or portfolio CEOs are the most efficient path in. The right time to engage is when the product is in market with early traction, when a customer or user base is forming, and when the next round will accelerate a working motion rather than discover one. Founders pitching pure clinical workflow, devices, or biotech will not find fit. Companies with no defensible technology spine beneath the consumer experience will struggle to clear diligence. For founders building genuinely tech-enabled wellness and digital health products with global consumer ambition, Firstime offers capital and a thesis-aligned partner.